Various Markers of Neuroendocrine Tumor: A Narrative Review

TL;DR

This review discusses various biomarkers for diagnosing and managing neuroendocrine tumors, which are rare and diverse cancers.

Contribution

The paper reviews current biomarkers for neuroendocrine tumors, emphasizing the need for specific and accurate diagnostic and prognostic tools.

Findings

Chromogranin A is a useful biomarker in the diagnostic process of neuroendocrine tumors.

There is a need for accurate biomarkers to improve diagnosis, prognosis, and treatment of neuroendocrine tumors.

The diversity of neuroendocrine tumors necessitates the development of specific biomarkers for effective management.

Abstract

Neuroendocrine tumors (NETs) are uncommon tumors that develop from specialized endocrine cells. Thyroid medullary carcinoma, phaeochromocytomas, pituitary tumors, carcinoid, and gastroenteropancreatic NET are just a few examples of the diverse group known as NET. In recent times, they have garnered significant interest due to their ease of palliation and ability to reveal the long-term impact of the specific hormone raised. Neuroendocrine indicators, particularly chromogranin A, are very helpful in the diagnostic process. Accurate biomarkers that can be employed for NET diagnosis, prognosis and follow-up, therapy stratification, and treatment response evaluation are greatly needed. Due to the great diversity of neuroendocrine neoplasms, particular biomarkers must be developed in order to diagnose, treat, and identify them. The several NET biomarkers covered in this review will aid in the fight against this uncommon illness.